


La molécule du mois - What molecule am I ?



Palbociclib

Palbociclib is a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with letrozole or fluvestrant. Palbociclib was approved by FDA in February 2015 as Ibrance® and is actually available in France via temporary authorisation for use (TAU).

Contribution : David MONTOIR January 2016